Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Impact of quadrivalent influenza vaccines in Brazil: a cost-effectiveness analysis using an influenza transmission model.

Tytuł :
Impact of quadrivalent influenza vaccines in Brazil: a cost-effectiveness analysis using an influenza transmission model.
Autorzy :
Crépey P; Department of Quantitative Methods in Public Health, UPRES-EA-7449 Reperes, EHESP, University of Rennes, 15 Av. Professeur Léon Bernard, 35043, Rennes, France.
Boiron L; Sanofi Pasteur, Av. das Nações Unidas, 14410 - Condomínio Parque da Cidade Torre Sucupira, Jardim Morumbi - CEP, São Paulo, SP, 04794-000, Brazil. .
Araujo RR; Sanofi Pasteur, Av. das Nações Unidas, 14410 - Condomínio Parque da Cidade Torre Sucupira, Jardim Morumbi - CEP, São Paulo, SP, 04794-000, Brazil.
Lopez JG; Sanofi Pasteur, Av. Universidad 1738, Santa Catarina, Coyoacán, 04000 Ciudad de México, CDMX, Mexico.
Petitjean A; Sanofi Pasteur, 14 Espace Henry Vallée, 69007, Lyon, France.
de Albuquerque Luna EJ; Institute of Tropical Medicine (IMT) - University of São Paulo (USP), Av. Dr. Enéas Carvalho de Aguiar, 470 - Jardim America - CEP, São Paulo, SP, 05403-000, Brazil.
Pokaż więcej
Źródło :
BMC public health [BMC Public Health] 2020 Sep 09; Vol. 20 (1), pp. 1374. Date of Electronic Publication: 2020 Sep 09.
Typ publikacji :
Journal Article
Język :
English
Imprint Name(s) :
Original Publication: London : BioMed Central, [2001-
MeSH Terms :
Cost-Benefit Analysis*
Influenza Vaccines*/economics
Influenza Vaccines*/immunology
Public Health*
Vaccination*/economics
Influenza, Human/*prevention & control
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Brazil/epidemiology ; Child ; Child, Preschool ; Economics, Medical ; Female ; Hospitalization/economics ; Humans ; Infant ; Influenza B virus/classification ; Influenza B virus/immunology ; Influenza, Human/economics ; Influenza, Human/epidemiology ; Influenza, Human/virology ; Middle Aged ; Models, Economic ; Quality-Adjusted Life Years ; Seasons ; Uncertainty ; Young Adult
References :
Am J Epidemiol. 2007 Jun 15;165(12):1434-42. (PMID: 17369609)
Vaccine. 2007 Jun 28;25(27):5086-96. (PMID: 17544181)
Lancet. 2018 Mar 31;391(10127):1285-1300. (PMID: 29248255)
PLoS One. 2011;6(7):e22308. (PMID: 21829456)
Influenza Other Respir Viruses. 2015 Aug;9 Suppl 1:13-21. (PMID: 26256291)
Vaccine. 2012 Dec 17;31(1):49-57. (PMID: 23142300)
PLoS One. 2017 Mar 27;12(3):e0174592. (PMID: 28346498)
Value Health. 2016 Dec;19(8):964-975. (PMID: 27987647)
PLoS One. 2015 Mar 04;10(3):e0118369. (PMID: 25738736)
PLoS One. 2009;4(4):e5095. (PMID: 19352506)
Hum Vaccin Immunother. 2017 Apr 3;13(4):877-888. (PMID: 28118092)
Influenza Other Respir Viruses. 2015 Aug;9 Suppl 1:39-46. (PMID: 26256294)
Braz J Infect Dis. 2018 Jan - Feb;22(1):1-10. (PMID: 29352897)
Influenza Other Respir Viruses. 2013 Nov;7(6):1017-32. (PMID: 23210504)
Hum Vaccin Immunother. 2017 Jun 3;13(6):1-12. (PMID: 28129026)
PLoS One. 2014 Jul 17;9(7):e102634. (PMID: 25032688)
PLoS One. 2016 Mar 31;11(3):e0152310. (PMID: 27031105)
Expert Rev Pharmacoecon Outcomes Res. 2017 Jun;17(3):249-265. (PMID: 28613092)
Emerg Infect Dis. 2009 Dec;15(12):2004-7. (PMID: 19961687)
Vaccine. 2012 Mar 2;30(11):1993-8. (PMID: 22226861)
Contributed Indexing :
Keywords: Brazil; Cost-effectiveness; Influenza; Public health; QIV; Quadrivalent; Vaccine
Substance Nomenclature :
0 (Influenza Vaccines)
Entry Date(s) :
Date Created: 20200910 Date Completed: 20201007 Latest Revision: 20201007
Update Code :
20201023
PubMed Central ID :
PMC7487874
DOI :
10.1186/s12889-020-09409-7
PMID :
32907562
Czasopismo naukowe
Background: Influenza epidemics significantly weight on the Brazilian healthcare system and its society. Public health authorities have progressively expanded recommendations for vaccination against influenza, particularly to the pediatric population. However, the potential mismatch between the trivalent influenza vaccine (TIV) strains and those circulating during the season remains an issue. Quadrivalent vaccines improves vaccines effectiveness by preventing any potential mismatch on influenza B lineages.
Methods: We evaluate the public health and economic benefits of the switch from TIV to QIV for the pediatric influenza recommendation (6mo-5yo) by using a dynamic epidemiological model able to consider the indirect impact of vaccination. Results of the epidemiological model are then imputed in a health-economic model adapted to the Brazilian context. We perform deterministic and probabilistic sensitivity analysis to account for both epidemiological and economical sources of uncertainty.
Results: Our results show that switching from TIV to QIV in the Brazilian pediatric population would prevent 406,600 symptomatic cases, 11,300 hospitalizations and almost 400 deaths by influenza season. This strategy would save 3400 life-years yearly for an incremental direct cost of R$169 million per year, down to R$86 million from a societal perspective. Incremental cost-effectiveness ratios for the switch would be R$49,700 per life-year saved and R$26,800 per quality-adjusted life-year gained from a public payer perspective, and even more cost-effective from a societal perspective. Our results are qualitatively similar in our sensitivity analysis.
Conclusions: Our analysis shows that switching from TIV to QIV to protect children aged 6mo to 5yo in the Brazilian influenza epidemiological context could have a strong public health impact and represent a cost-effective strategy from a public payer perspective, and a highly cost-effective one from a societal perspective.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies